Saturday, February 11, 2017 3:28:54 PM
Source: GB Sciences
GB Sciences has three distinctive factors that play into the Company's favor moving forward:
Current Revenue & Products
Standardized Supply Chain, Ensuring Safe and Effective Cannabis Products
Streamlined Approach to Research and Development of Drug Candidates
The Company's experienced management team has implemented a strategy that most biotech companies don't have the option to adopt. On January 4, 2017, the Company announced the certification of their grow facility located in Las Vegas, NV. The facility is anticipated to begin generating revenue within the next 3 months. When the facility is operating at full capacity, the Company projects revenue generation of $20+m annually from this facility alone. Of note, this new grow facility utilizes a scientific-based approach, with processes and controls designed to meet strict cGMP and ISO 9001:2015 qualifications. The Company has implemented a cultivation and production process that reduces the degradation of plant genetics (aka "genetic drift") designed to deliver consistency in its products. The process includes a combination of tissue culture, micro-propagation, and strict environmental controls. As the company heads to FDA-approved clinical trials, the ability to produce a consistent and truly standardized product is imperative. (More about this later.)
Additionally, the Company has announced a partial ownership of an operational dispensary facility in Nevada, however the Company has yet to provide guidance on this business opportunity.
The Company anticipates initial revenue from their grow operation beginning as soon as the end of the 1st quarter of the year, and ramping up over the course of 2017. The grow, along with other initiatives, is anticipated to provide the Company an adequate cash flow to fund growth and ongoing R&D expenses, as GB formulates new products and explores therapies for a wide range of serious medical conditions.
The GB management team has also leveraged one of the advantages of operating within the state-regulated medical cannabis environment. With cannabis-based therapies able to be made available without the FDA's approval, the Company's products can be accessible by patients immediately, upon formulation. GB has developed a two-pronged approach on bringing therapeutic products to market. First: GB plans to release some formulations of therapies directly to the marketplace, which generates revenue without the delay of going through an approval process. The Company has adopted a smartphone app and tools where patients will be able to track and report their responses to the different therapies the Company plans to introduce. The information provided is expected to be very beneficial as the Company advances its research and development pipeline. With the revenues anticipated from its grow operations, bolstered by therapeutic product sales, GB's second strategy is to be able to fund development of therapies through a fully approved FDA process. GB's management is optimistic the FDA will allow the Company's smartphone app, and more importantly the data gathered from it, to be utilized in some aspects of pre-clinical, Human Phase I, Phase II, and Phase III trials, which would aide in both the speed and expense burden of going through the FDA approval process.
The Company has already filed its initial patent on a cannabinoid-based therapy for the treatment of Parkinson's Disease, and is working to initiate a FDA-approved pilot study within the year. While GB is planning to target Parkinson's Disease in the study, the Company believes the therapy formulated may also be effective in treating Alzheimer's Disease, and Lewy Body Dementia, among other neurological disorders. According to a March 2016 article in Drug Discovery & Development, the Parkinson's Disease drug market is projected to be $3.2B by 2021, up from $2.1B in 2014.
Recent GBLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:15:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 06:31:48 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2023 08:18:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:12:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/30/2023 12:00:24 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM